. home about key facts organization company history technology human health animal health press room funding contact trophogen seeks 1 5 million in venture debt mezzanine financing series b investment and or pharmaceutical partnership to develop three advanced human glycoprotein analog biosuperior products for infertility and untreatable cancers using a new expedited fda 505 b 2 nda regulatory pathway . may 17th 2016 rockville md trophogen has a unique and very broad platform technology to develop patented long acting much more potent & effective and totally safe non immunogenic human and animal superagonist analogs of glycoprotein hormones and growth factors . the company is seeking investments to address multi billion dollar markets in infertility elective egg banking and untreatable & aggressive cancers . the first 3 human products of this very broad platform fsh tsh and vegf superagonist analogs plus nanotechnology are fully developed and ready for ind and clinical trials . trophogen s biosuperior platform technologies will supercede all current biobetters biosimilars and current market drugs in their respective imaging diagnostic and therapeutic space . click here to download trophogen s pitch deck pdf trophogen inc. awarded 756 000 for second year of phase 2 nih nci fast track sbir grant for development of novel human vegf analogs for targeted imaging of undifferentiated thyroid cancer . july 7th 2015 for immediate rlease rockville md trophogen inc. today announced that it was awarded the second year of its phase 2 fast track component of 756 000 for a small business innovation research sbir award from the national cancer institute nci of the national institutes of health nih to develop novel vegf analogs for targeted imaging of undifferentiated thyroid cancer . read more trophogen inc. announces signing of exclusive global veterinary license and purchase agreement with zoetis inc. for recombinant long acting and superactive bovine follicle stimulating hormone rbfsh analog for superovulation in cows . june 2nd 2015 for immediate rlease rockville md trophogen inc. today announced that the company has completed a licensing and purchase agreement granting zoetis inc. the leading global animal health company an exclusive license to develop trophogen s recombinant modified bovine follicle stimulating hormone rbfsh analog in the field of animal health reproduction . read more lead products 1 . recombinant long acting high potency bovine fsh super agonist analog for superovula tion and embryo transfer in beef and dairy cows licensed to zoetis inc. see above . 2 . recombinant long acting high potency equine cg super agonist analog for reduced time to & synchronization of estrus in pigs and other animals . 3 . recombinant long acting high potency human fsh super agonist analog for infertility and elective egg banking . 4 . recombinant long acting high potency human tsh super agonist analog for imaging and treatment of thyroid cancer . click for full listing of human or animal products . trophogen inc. 2015 sharethis copy and paste